Slingshot members are tracking this event:

ZIOPHARM Reports 2 Patient Deaths in its Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
"This Phase I study is being conducted in late-stage, recurrent GBM, so these patients are all, unfortunately, medically fragile. The first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug. A third death has just been reported to us and we are collecting and analyzing information in order to properly and timely report it to the FDA. The cause of death is intracranial hemorrhage, which occurred some time after the patient had been discharged from the treating center. This is an isolated case, and there have been no reported related instances of brain hemorrhage in any pervious cohort or prior studies with Ad-RTS-hIL-12 + veledimex. Enrollment remains open in the study, and we will be discussing with our Safety Review Committee the appropriate course of action. For patients who have experienced multiple recurrences, as these patients have, prognoses are particularly poor. Median follow up in the first dose cohort from our study is now 8 months, in a population with an expected overall survival of 3 to 5 months for patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy. For the patients that remain in follow up in this Phase I study, we believe that preliminary overall survival remains encouraging. The Company expects to provide an update once a course of action has been determined."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ad-rts-hil-12, Gene Therapy, Brain Cancer, Veledimex, Progressive Glioblastoma, Grade Iii Malignant Glioma